Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation

Journal of Heart and Lung Transplantation

Volumn 32, Issue 7, 2013, Pages 701-706

  Ghassemieh, Bijan ^a   Ahya, Vivek N ^b   Baz, Maher A ^c   Valentine, Vincent G ^d   Arcasoy, Selim M ^e   Love, Robert B ^f   Seethamraju, Harish ^g   Alex, Charles G ^f   Bag, Remzi ^h   Deoliveira, Nilto C ⁱ   Vigneswaran, Wickii T ^a   Charbeneau, Jeff ^j   Garrity, Edward R ^a   Bhorade, Sangeeta M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j UNIVERSITY OF ILLINOIS   (United States)

more..

Author keywords

azathioprine; cytomegalovirus; lung transplantation; sirolimus

Indexed keywords

AZATHIOPRINE; RAPAMYCIN;

ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DATA BASE; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; MORBIDITY; POST HOC ANALYSIS; PRIORITY JOURNAL;

CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 84879696144     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.04.010     Document Type: Article

References (33)

1. M.R. Zamora Cytomegalovirus and lung transplantation Am J Transplant 8 2004 1219 1226
2. D.R. Snydman, A.P. Limaye, and L. Potena Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation Transplant Proc 43 suppl 2011 S1 17
3. J.A. Fishman, V.C. Enery, and R. Freeman Cytomegalovirus in transplantation: challenging the status quo Clin Transplant 21 2007 149
4. N. Singh Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies J Clin Virol 35 2006 474 477
5. R.H. Rubin The indirect effects of cytomegalovirus infection on the outcome of organ transplantation JAMA 261 1989 3607
6. T. Reischeg, P. Jindra, and M. Svecova The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection J Clin Virol 36 2006 146
7. L.D. Snyder, C.A. Finlen-Copeland, and W.J. Turbyfill Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation Am J Respir Crit Care Med 181 2010 1391 1396
8. S.M. Palmer, A.P. Limaye, and M. Banks Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation Ann Intern Med 152 2010 761 769
9. A. Finlen-Copeland, A. Davis, and L.D. Snyder Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single center long term follow up analysis from a randomized, controlled cytomegalovirus prevention trial J Heart Lung Transplant 30 2011 990 996
10. S.M. Bhorade, N.S. Lurain, and A. Jordan Emergence of ganciclovir resistant cytomegalovirus in lung transplant recipients J Heart Lung Transplant 21 2002 1274 1283
11. H.A. Myhre, D. Haug Dorenberg, and K.I. Kristiansen Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients Transplantation 92 2011 217 223
12. D.C. Brennan, C. Legendre, and D. Patel Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials Am J Transplant 11 2011 2453 2462
13. S. Vitko, R. Margreiter, and W. Weimar Three year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients Am J Transplant 10 2005 2521 2530
14. R. San Juan, J.M. Aguado, and C. Lumbreras Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation Clin Infect Dis 47 2008 875 882
15. A.C. Webster, V.W.S. Lee, and J.R. Chapman Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials Transplantation 81 2006 1234 1248
16. H.J. Eisen, E.M. Tuzcu, and R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients N Engl J Med 349 2003 847 858
17. J.A. Hill, M. Hummel, and R.C. Starling A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus Transplantation 84 2007 1436 1442
18. M. Vigano, T. Dengler, and M.F. Mattei Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study Transpl Infect Dis 12 2010 23 30
19. L. Demopoulos, M. Polinsky, and G. Steele Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials Transplant Proc 40 2008 1407 1410
20. F.M. Marty, J. Bryar, and S.K. Browne Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis Blood 110 2007 490 500
21. S. Sehgal Ramamure (sirolimus, rapamycin): an overview and mechanism of action Ther Drug Monitor 17 1995 660 665
22. F.J. Dumont, M.J. Staruch, and S.L. Koprak Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin J Immunol 144 1990 251 258
23. R.N. Saunders, M.S. Metcalfe, and M.L. Nicholson Rapamycin in transplantation: a review of the evidence Kidney Int 59 2001 3 16
24. M. Poglitsch, T. Weichhart, and M. Hecking CMV late phase induced mTOR activation is essential for efficient virus replication in polarized human macrophages Am J Transplant 12 2012 1458 1468
25. S. Bhorade, V.N. Ahya, and M.A. Baz Comparison of sirolimus to azathioprine in a tacrolimus based immunosuppressive regimen in lung transplantation Am J Respir Crit Care Med 183 2011 379 387
26. A. Humar Michaels M on behalf of the AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation Am J Transplant 6 2006 262 274
27. G.I. Snell, V.G. Valentine, and P. Vitulo Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double blind clinical trial Am J Transplant 6 2006 169 177
28. M.S. Smith, G.L. Bentz, and P.M. Smith HCMV activates PI(3)K in monocytes and promotes monocyte motility and transendothelial migration in a PI(3)K-dependent manner J Leukoc Biol 76 2004 65 76
29. J.V. Spencer The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes J Virol 81 2007 2083 2086
30. S.M. Kudchodkar, Y. Yu, and T.G. Maguire Human cytomegalorivus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes Proc Natl Acad Sci USA 103 2006 14182 14187
31. E. Iodinkova, M.C. Arcangeletti, and A. Rynditch Control of human cytomegalovirus gene expression by differential histone modifications during lytic and latent infection of a monocytic cell line Gene 384 2006 120 128
32. M.B. Reeves, P.A. MacAry, and P.J. Lehner Latency, chromatin, remodeling and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers Proc Natl Acad Sci USA 102 2005 4140 4145
33. K.S. Ozaki, N.O. Camara, and E. Nogueira The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients Clin Transplant 21 2007 675 680